| Literature DB >> 32806608 |
Mohamed Nadjib Boukhatem1,2, Thangirala Sudha1, Noureldien H E Darwish1,3, Henni Chader4,5, Asma Belkadi6, Mehdi Rajabi1, Aicha Houche2, Fatma Benkebailli2, Faiza Oudjida7, Shaker A Mousa1.
Abstract
BACKGROUND/AIM: natural products are a potential source for drug discovery and development of cancer chemoprevention. Considering that drugs currently available for the treatment of inflammatory and cancer conditions show undesirable side effects, this research was designed to evaluate, for the first time, the in vitro anticancer activity of Algerian Lavandula stoechas essential oil (LSEO) against different cancer cell lines, as well as its in vitro and in vivo topical and acute anti-inflammatory properties.Entities:
Keywords: 1,8-Cineole; Lavandula stoechas essential oil; anticancer activity; melanoma cell lines; topical anti-inflammatory effect
Mesh:
Substances:
Year: 2020 PMID: 32806608 PMCID: PMC7463424 DOI: 10.3390/molecules25163671
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Chemical composition of the volatile oil extracted from Lavandula stoechas using a steam distillation method.
| Retention Time (min) | Name | % |
|---|---|---|
| 8.874 | α-Pinene | 4.75 |
| 9.155 | Camphene | 0.35 |
| 9.808 | β-Pinene | 13.83 |
| 11.031 | 1,8-Cineole | 61.36 |
| 11.640 | 0.92 | |
| 11.887 | 1.39 | |
| 12.114 | Linalool | 1.63 |
| 12.475 | α-Campholenal | 0.44 |
| 12.734 | Pinocarveol | 2.12 |
| 12.778 | Camphor | 0.63 |
| 13.067 | Pinocarvone | 2.04 |
| 13.181 | α-Terpineol | 3.15 |
| 13.288 | Terpineol-4 | 0.96 |
| 13.453 | Cryptone | 0.59 |
| 13.532 | α-Terpineol | 1.14 |
| 13.598 | Myrtenal | 2.36 |
| 13.781 | Verbenone | 0.29 |
| 14.261 | Carvone | 0.21 |
| 17.442 | Aromadendrene | 0.98 |
| 17.749 | δ-Elemene | 0.66 |
| 17.863 | 0.20 | |
| Oxygenated Monoterpenes | 79.23 | |
| Monoterene Hydrocarbons | 18.93 | |
| Sesquiterpene Hydrocarbons | 1.84 |
Figure 1The chemical profile of Lavandula stoechas essential oil extracted using steam distillation. (X-axis in minutes).
Effect of LSEO on stabilization of HRBC membrane in vitro.
| Treatment | Concentration | Absorbance | % Inhibition | IC50 # |
|---|---|---|---|---|
|
| 0.568 | - | - | |
| LSEO | 6 | 0.370 | 34.917 ± 1.939 D | 6.214 ± 0.776 B |
| 3 | 0.145 | 74.471 ± 0.465 C | ||
| 1.5 | 0.064 | 88.791 ± 0.101 B | ||
| 0.8 | 0.042 | 92.605 ± 0.000 A | ||
| 0.4 | 0.042 | 92.605 ± 0.465 A | ||
| Sodium diclofenac | 30 | 0.46 | 19.014 ± 12.707 F | 1.198 ± 0.735 A |
| 3 | 0.411 | 27.552 ± 3.354 E | ||
| 0.3 | 0.045 | 92.165 ± 0.419 A | ||
| 0.03 | 0.041 | 92.693 ± 0.227 A | ||
| 0.003 | 0.04 | 92.913 ± 0.221 A |
Each value represents the mean ± SD. LSEO: Lavandula stoechas Essential Oil. IC50: Median Inhibitory Concentration; HRBC: Human Red Blood Cells; PBS: phosphate-buffered saline. # Means within the same column followed by the same letter are not significantly different (p > 0.05) according to ANOVA analysis followed by Tukey’s post hoc multiple comparison tests.
Effect of LSEO on heat-induced protein denaturation.
| Treatment | Concentration | Absorbance | % Inhibition | IC50 # |
|---|---|---|---|---|
|
| 1.288 | - | - | |
| LSEO | 6 | 0.067 | 62.569 ± 0.967 E | 2.447 ± 0.873 A |
| 3 | 0.061 | 65.735 ± 0.853 D | ||
| 1.5 | 0.054 | 69.832 ± 0.558 C | ||
| 0.8 | 0.048 | 73.184 ± 0.558 B | ||
| 0.4 | 0.049 | 72.625 ± 2.560 B | ||
| Sodium diclofenac | 10 | 0.165 | 7.960 ± 7.741 F | 8.260 ± 0.943 B |
| 1 | 0.04 | 77.932 ± 0.721 A | ||
| 0.1 | 0.044 | 75.279 ± 2.555 A | ||
| 0.01 | 0.043 | 76.117 ± 0.534 A | ||
| 0.001 | 0.045 | 74.720 ± 0.279 AB |
Each value represents the mean ± SD. LSEO: Lavandula stoechas Essential Oil. IC50: Median Inhibitory Concentration; BSA: Bovine Serum Albumin. # Means within the same column followed by the same letter are not significantly different (p > 0.05) according to ANOVA analysis followed by Tukey’s post hoc multiple comparison tests.
In vivo anti-inflammatory effect of LSEO using carrageenan induced-paw edema.
| Treatment | Weight (mean, mg) ± SD | % Inhibition | ||
|---|---|---|---|---|
| Left Hind Paw | Right Hind Paw | Edema Weight # | ||
| LSEO (200) | 126.10 ± 8.00 | 110.12 ± 7.12 | 15.975 ± 7.31 A | 47.0588 |
| LSEO (20) | 138.48 ± 10.1 | 121.00 ± 6.72 | 17.480 ± 8.71 A | 42.0712 |
| LSEO (2) | 146.08 ± 8.61 | 122.35 ± 6.00 | 23.733 ± 9.22 A,B | 21.3476 |
| Positive control | 161.25 ± 6.12 | 144.50 ± 6.18 | 16.750 ± 7.50 A | 44.4904 |
| Negative control | 154.30 ± 7.65 | 124.12 ± 10.0 | 30.175 ± 13.41 B | / |
Groups of animals (n = 5 mice per group) were pretreated with vehicle, Indomethacin (25 mg/kg, p.o.) or LSEO at doses of 2, 20, and 200 mg/kg per os (p.o.) 30 min before carrageenan-induced paw edema. LSEO: Lavandula stoechas Essential Oil. # Means within the same column followed by the same capital letter are not significantly different (p > 0.05) according to ANOVA analysis followed by Tukey’s post hoc multiple comparison test.
Lavandula stoechas aromatic oil prevents xylene-induced ear edema in mice.
| Treatment | Weight (mean, mg) ± SD | % Inhibition | ||
|---|---|---|---|---|
| Left Ear | Right Ear | Edema Weight # | ||
| LSEO (820) | 22.97 ± 4.13 | 16.52 ± 0.73 | 6.45 ± 2.80 B | 25.8620 |
| LSEO (410) | 16.37 ± 1.92 | 14.65 ± 2.22 | 1.72 ± 1.20 A | 80.1724 |
| LSEO (82) | 22.72 ± 5.16 | 18.50 ± 1.99 | 4.22 ± 2.88 B | 51.4367 |
| Betasone® 0.5% | 18.08 ± 2.79 | 15.50 ± 1.50 | 2.58 ± 1.49 A,B | 70.3448 |
| Voltarene Emulgel® 1% | 20.70 ± 4.94 | 13.32 ± 1.35 | 7.38 ± 3.17 B | 15.1724 |
| Negative control (Vehicle) | 28.10 ± 6.12 | 19.40 ± 4.13 | 8.70 ± 3.55 C | / |
Data are presented as Mean (mg) ± Standard Deviation (SD) (n = 5 mice per group). LSEO: Lavandula stoechas Essential Oil. # Means within the same column followed by the same capital letter are not significantly different (p > 0.05) according to ANOVA one way analysis followed by Tukey’s post hoc multiple comparison test.
Figure 2Sections of mice ear biopsies showing keratin, epidermal, dermal, muscle, and cartilage layers. Hematoxylin & Eosin stained sections were scored as mild (+), modest (++), and severe (+++) for edema and substantial inflammatory polymorphonuclear (PMN) cell infiltration in the dermis inflammation phase. (1) Keratin; (2) epidermal layer; (3) cartilage layer; (4) PMN; (5) edema; (6) muscle. (A) Right ear without treatment (×10). (B) Lavandula stoechas Essential Oil (LSEO) treatment with different doses (B1): LSEO 82 mg/kg (G × 10), (B2): LSEO 410 mg/kg (G × 10), (B3): LSEO 810 mg/kg (G × 10)) = edema (±); inflammatory cell infiltration (+), inflammation phase (±). (C) Positive control treatment (C1): Voltarène Emulgel (G × 10); (C2): betamethasone (G × 40) = edema (±); inflammatory cell infiltration (+), inflammation phase (±). (D1) Negative control (×10) = edema (++); inflammation phase (+++); inflammatory cell infiltration (+++) in epidermal and dermal layers, muscle, and cartilage. (D2) Negative control (×40). Scale − bar = 25 µm; black arrow indicates inflammatory polymorphonuclear cell infiltration.
Figure 3In vitro cytotoxic effect of LSEO against different cancer cell lines using MTT assay. IC50: Median inhibitory concentration. Experiments were performed three times in octuplets.
Figure 4Anti-proliferative activity of LSEO after 24 h of exposure in the MTT assay. MDA-MB-231: human breast carcinoma cells; MV3: human melanoma; AGS: human gastric cancer. Experiments were performed three times in octuplets.